Jefferies raised the firm’s price target on Neurocrine to $123 from $122 and keeps a Buy rating on the shares. Ingrezza was approved for the treatment of chorea associated with Huntington’s disease, or HD, as expected, but it “was a bit surprising” that Ingrezza got a VMAT2 class black box warning for depression and suicidal ideation and behavior for the HD indication, the analyst tells investors. Jefferies models peak sales of $332M for Ingrezza in HD Chorea, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Stock (NASDAQ:NBIX): Investors and Analysts are Bullish
- Neurocrine price target raised at BofA after new Ingrezza indication approved
- Neurocrine black box warning for Huntington’s a surprise, says Mizuho
- Neurocrine price target raised to $154 from $150 at Oppenheimer
- Neurocrine price target raised to $146 from $140 at H.C. Wainwright